0000315066-16-004779.txt : 20160210
0000315066-16-004779.hdr.sgml : 20160210
20160210215943
ACCESSION NUMBER: 0000315066-16-004779
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160210
FILED AS OF DATE: 20160210
DATE AS OF CHANGE: 20160210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-225-0096
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FMR LLC
CENTRAL INDEX KEY: 0000315066
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 161407706
BUSINESS ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6175706339
MAIL ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER NAME:
FORMER CONFORMED NAME: FMR CORP
DATE OF NAME CHANGE: 19920717
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0206
3
2016-02-10
0
0001445283
PROTEOSTASIS THERAPEUTICS, INC.
PTI
0000315066
FMR LLC
245 SUMMER STREET
BOSTON
MA
02210
0
0
1
1
See Remark 1
Series A Convertible Preferred Stock
Common Stock
1318932
I
F-Prime Capital Partners Healthcare Fund II LP
Series B Convertible Preferred Stock
Common Stock
183880
I
F-Prime Capital Partners Healthcare Fund II LP
Shares of Series A and B Convertible Preferred Stock are convertible into shares of Common Stock at a 10.8102-for-one conversion ratio as shown in Table II, at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and have no expiration date.
Includes 925,051 shares of Common Stock underlying the Series A Convertible Preferred Stock and 393,881 shares of Common Stock issuable as payment of accruing dividends due upon conversion of the Series A Convertible Preferred Stock.
Remark 1: Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110.
Remark 2: F-Prime Capital Partners Healthcare Advisors Fund II LP is the general partner of F-Prime Capital Partners Healthcare Fund II LP. F-Prime Capital Partners Healthcare Advisors Fund II LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.
Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
2016-02-10